Abstract 7P
Background
Neutrophil extracellular traps (NETs) are involved in the progression and metastasis of a variety of malignancies. Our previous studies have confirmed that tumor cell-released autophagosomes (TRAPs) induced immunosuppression TME formation. However, it remains to be investigated whether TRAPs-treated neutrophils contribute to the metastatic colonization of the lungs by tumor cells.
Methods
NETs were observed by scanning electron microscopy (SEM) and Confocal Microscope. Western blot and ELISA were used to quantify MPO-DNA, NE, and cit-H3 which are important components of NETs. In vivo, TRAPs were injected into the tail vein of mice and Beclin1 knockdown 4T1 tumor cells engineering to reduce TRAPs release were injected into mice subcutaneously. The characteristic molecules of NETs in plasma were detected. The study used antibody blocking assays and HMGB1 knockdown cell lines to identify key DAMPs on the surface of TRAPs. Inhibitor-treated neutrophils and TLR4 knockout mice were used to identify functional receptors on neutrophils. Flow cytometry was used to evaluate the effect of TRAPs on T cell function and lung infiltrating T cell function, as well as to monitor late lung metastases in neutrophils treated with TRAPs suppressor.
Results
Numerous reticular structures significantly increased in the cell culture supernatant after TRAPs treatment. In vivo, NETs were significantly increased in plasma after tail vein injection of TRAPs as well as in 4T1 tumor-bearing mice. Conversely, NETs were significantly decreased in the plasma of Beclin1 knockdown 4T1 tumor-bearing mice. TRAPs derived from breast tumor cell lines induced neutrophil formation of NETs via the HMGB1-TLR4-MyD88-ERK/p38 pathway. This process inhibited the proliferation and secretion of IFN-γ in CD4+ and CD8+ T cells, ultimately leading to increased lung metastasis.
Conclusions
Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation. Overall, these findings define a novel mechanism mediated by TRAPs in neutrophils, which may suppress anti-tumor T cell immunity and highlight TRAPs as an important target for future tumor immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Wu, X. Wang.
Funding
Supported by National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract